Preliminary Data: Anti-VEGF Eyedrop for Wet AMD Treatment Showed No Safety Concerns

 

No treatment-related adverse events have been reported in a phase 1/2 study evaluating the anti-VEGF eyedrop PAN-90806 (PanOptica) for the treatment of neovascular AMD. Anti-VEGF biological activity was observed in all monotherapy dose arms of the study. A full data set will be available in 2016.

According to the company’s president and CEO, Paul Chaney, PanOptica is developing an advanced, next-generation formulation of PAN-90806 for use in future trials. Mr. Chaney also reported that the company has initiated a phase 1 trial of PAN-90806 in patients with proliferative diabetic retinopathy.

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.